Boston Scientific Co. (NYSE:BSX) Stake Lifted by Northwest & Ethical Investments L.P.

Northwest & Ethical Investments L.P. increased its stake in shares of Boston Scientific Co. (NYSE:BSX) by 0.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 74,428 shares of the medical equipment provider’s stock after buying an additional 330 shares during the quarter. Northwest & Ethical Investments L.P.’s holdings in Boston Scientific were worth $6,647,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Empowered Funds LLC boosted its position in Boston Scientific by 7.9% during the 3rd quarter. Empowered Funds LLC now owns 23,413 shares of the medical equipment provider’s stock worth $1,962,000 after acquiring an additional 1,715 shares during the period. Avior Wealth Management LLC boosted its position in Boston Scientific by 3.9% during the 3rd quarter. Avior Wealth Management LLC now owns 11,632 shares of the medical equipment provider’s stock worth $975,000 after acquiring an additional 436 shares during the period. Connor Clark & Lunn Investment Management Ltd. boosted its position in Boston Scientific by 839.1% during the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 218,756 shares of the medical equipment provider’s stock worth $18,332,000 after acquiring an additional 195,461 shares during the period. Advisors Asset Management Inc. lifted its holdings in shares of Boston Scientific by 21.3% in the third quarter. Advisors Asset Management Inc. now owns 24,060 shares of the medical equipment provider’s stock valued at $2,016,000 after buying an additional 4,233 shares during the period. Finally, Citizens Financial Group Inc. RI lifted its holdings in shares of Boston Scientific by 41.4% in the third quarter. Citizens Financial Group Inc. RI now owns 5,039 shares of the medical equipment provider’s stock valued at $422,000 after buying an additional 1,475 shares during the period. 89.07% of the stock is currently owned by institutional investors.

Boston Scientific Stock Up 0.8 %

NYSE:BSX opened at $101.55 on Friday. The firm has a market capitalization of $149.86 billion, a price-to-earnings ratio of 81.24, a PEG ratio of 2.79 and a beta of 0.77. Boston Scientific Co. has a 1-year low of $66.80 and a 1-year high of $107.17. The company has a current ratio of 1.08, a quick ratio of 1.02 and a debt-to-equity ratio of 0.41. The business’s fifty day moving average price is $101.57 and its 200 day moving average price is $92.22.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.65 by $0.05. Boston Scientific had a return on equity of 17.80% and a net margin of 11.07%. On average, sell-side analysts forecast that Boston Scientific Co. will post 2.85 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently weighed in on BSX shares. TD Cowen upped their price objective on Boston Scientific from $100.00 to $110.00 and gave the company a “buy” rating in a report on Thursday, December 12th. Piper Sandler upped their price objective on Boston Scientific from $95.00 to $115.00 and gave the company an “overweight” rating in a report on Monday, February 3rd. Barclays upped their price objective on Boston Scientific from $111.00 to $118.00 and gave the company an “overweight” rating in a report on Monday, February 10th. Needham & Company LLC restated a “hold” rating on shares of Boston Scientific in a report on Monday, March 3rd. Finally, Raymond James upped their target price on Boston Scientific from $119.00 to $122.00 and gave the company a “strong-buy” rating in a report on Thursday, February 6th. Two analysts have rated the stock with a hold rating, twenty-one have given a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, Boston Scientific presently has an average rating of “Moderate Buy” and a consensus price target of $108.91.

Insiders Place Their Bets

In other Boston Scientific news, EVP John Bradley Sorenson sold 4,119 shares of the company’s stock in a transaction dated Thursday, January 2nd. The stock was sold at an average price of $90.02, for a total value of $370,792.38. Following the transaction, the executive vice president now directly owns 35,319 shares of the company’s stock, valued at $3,179,416.38. This represents a 10.44 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CFO Daniel J. Brennan sold 15,087 shares of the company’s stock in a transaction dated Wednesday, February 12th. The stock was sold at an average price of $105.07, for a total value of $1,585,191.09. Following the completion of the transaction, the chief financial officer now directly owns 241,451 shares in the company, valued at approximately $25,369,256.57. The trade was a 5.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 137,302 shares of company stock valued at $14,319,269 in the last three months. Insiders own 0.50% of the company’s stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.